Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology AG: Novartis buys out CAD 106 license agreement for CHF 4 million

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Agreement
Cytos Biotechnology AG: Novartis buys out CAD 106 license agreement
for CHF 4 million

25.03.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

Schlieren (Zurich), Switzerland, March 25, 2015 - Cytos Biotechnology Ltd
("Cytos") today announced that Novartis has agreed to make a one-time
payment of CHF 4 million to eliminate any further payment obligations under
the Collaborative Research, Option and License Agreement for CAD106, which
is under development by Novartis for the prevention of Alzheimer's disease.

Cytos is planning to use the payment from Novartis to settle remaining
payment obligations under the outstanding convertible loan notes, which
remain subordinated.

The closing of the transaction with Novartis is expected to occur upon the
conversion of the convertible bonds into Cytos shares in the second half of
April 2015 and certain other closing conditions.



For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=KAFNOJKSCK
Document title: Cytos_CAD106_150325

---------------------------------------------------------------------

25.03.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news
archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
336909 25.03.2015
 



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: